organ transplant | GenomeWeb

organ transplant

The firm saw a 6 percent boost year over year in test volumes for its AlloMap non-invasive blood test for heart transplant patients.

Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx’s cfDNA testing workflows for the monitoring of transplanted organ rejection.

A team led by Stanford's Mike Snyder is collaborating with investigators from the International Genetics & Translational Research in Transplantation Network (iGeneTrain) consortium.

The company had previously said it intended to use the proceeds to continue its development of its solid organ transplant diagnostic AlloSure. 

The company said it achieved record volumes for its AlloMap non-invasive blood test for heart transplant patients.

The partners will work together to see whether cell-free DNA levels can be used to predict organ injury in kidney transplantation and improve clinical outcomes.

The collaboration will use Transplant Genomics' TruGraf test for post-kidney transplant monitoring to try to personalize immunosuppression therapies.

The companies will combine Qiagen's QIAxcel and CareDx's Olerup SSP kits and Score software into an HLA typing product offering for transplant labs.

The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.

Transplant Genomics will use its TruGraf blood test to help Astellas evaluate patient outcomes in a study of its immunosuppressive drug Astagraf XL.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.